3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
19
Recruiting
5
Terminated
4
Unknown
3
Withdrawn
2
No longer available
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
Conditions
Sarcoma
3
Ovarian Neoplasms
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Fanconi Anemia, Complementation Group D1
1
Chondrosarcoma
1
Bone Neoplasms
1
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Etoposide
3
Docetaxel
3
ribociclib
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Gene Expression Profiling
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
Trabectedin
×
Clear all
NCT03985722
2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1
Unknown
28 enrolled
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled
NCT02359474
2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2
Unknown
120 enrolled